Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00

Cullinan Therapeutics (NASDAQ:CGEM) had its price objective boosted by investment analysts at Wedbush from $39.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target indicates a potential upside of 114.29% from the company’s current price.

CGEM has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Cullinan Therapeutics in a research report on Monday, June 8th. BTIG Research upped their target price on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Finally, Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.86.

Cullinan Therapeutics Trading Down 0.2%

Shares of CGEM opened at $19.60 on Thursday. The firm has a market cap of $1.26 billion, a P/E ratio of -6.32 and a beta of 0.01. The stock’s 50 day moving average is $16.81 and its two-hundred day moving average is $14.99. Cullinan Therapeutics has a 12 month low of $5.68 and a 12 month high of $19.94.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). Equities research analysts forecast that Cullinan Therapeutics will post -3.03 EPS for the current year.

Insiders Place Their Bets

In related news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the transaction, the insider directly owned 162,844 shares in the company, valued at approximately $2,901,880.08. This represents a 4.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd increased its position in shares of Cullinan Therapeutics by 62.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after purchasing an additional 1,036 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in Cullinan Therapeutics during the fourth quarter worth about $31,000. CWM LLC boosted its stake in Cullinan Therapeutics by 51.5% during the fourth quarter. CWM LLC now owns 3,876 shares of the company’s stock worth $40,000 after buying an additional 1,318 shares during the period. Allworth Financial LP acquired a new stake in shares of Cullinan Therapeutics during the second quarter valued at about $53,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Cullinan Therapeutics in the 2nd quarter valued at approximately $53,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

More Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analysts currently assign Cullinan Therapeutics an average rating of “Moderate Buy”, indicating generally favorable sentiment toward the biotechnology company’s pipeline and longer-term prospects. Cullinan Therapeutics Receives Average Rating of Moderate Buy from Analysts
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $30 price target for CGEM, implying substantial upside from the stock’s recent level around $19.60. The firm’s published estimates show expected losses narrowing modestly during 2027, although the company is still projected to remain unprofitable. HC Wainwright analyst estimates for Cullinan Therapeutics
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio. Because the data showed no measurable short position and an unusable percentage change, it provides little meaningful indication of investor positioning or likely trading pressure.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $3.53 per share from a $3.42 loss, and reduced its Q3 2026 forecast to a $0.90 loss from $0.87. The firm also cut its Q4 2026 estimate to a $0.93 loss from $0.90, signaling somewhat higher expected near-term expenses.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.